Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 19/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 16/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 14/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 1.00 |
| ▸ | NCOR2 | Q9Y618 | 7/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 6/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 1.00 |
| ▸ | UBA1 | P22314 | 1/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Largazole SCHEMBL7937167 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6NCOR2 | |
| Largazole SCHEMBL2611944 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6NCOR2 | |
| Largazole SCHEMBL31485751 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6NCOR2 | |
| Largazole SCHEMBL91139 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6NCOR2 | |
| Largazole SCHEMBL23760411 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6NCOR2 | |
| Largazole SCHEMBL23760414 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6NCOR2 | |
| Largazole SCHEMBL10314988 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6NCOR2 | |
| Largazole SCHEMBL14973971 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6NCOR2 | |
| Largazole SCHEMBL2611945 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6NCOR2 | |
| SCHEMBL13453167 | 0.97 | HDAC1 (0.94) | HDAC1HDAC3HDAC2HDAC6NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 458 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695324-A1 | BIO-ORTHOGONAL HYDROGELS FOR SUSTAINED RELEASE DRUG DELIVERY | Ocular Therapeutix, Inc. (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4683964-A2 | POLY(ETHYLENE GLYCOL) BASED DENDRIMER-LIKE HYPERBRANCHED MACROMOLECULES, METHODS OF PREPARATION AND USE THEREOF | Ocular Therapeutix, Inc. (US) | 2026-01-28 | — | — | EP | claimed |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | claimed |
| US-20250144056-A1 | ANTIMICROBIAL HOST DEFENSE PEPTIDE-INDUCING COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF | BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECH COLLEGES (US) | 2025-05-08 | — | — | US | claimed |
| CN-119923405-A | Treatment or prevention of medical conditions associated with herpes virus infection | 艾克西米恩生物技术股份有限公司 | 2025-05-02 | — | — | CN | claimed |
| WO-2025059442-A1 | MODULATING PLANT RESPONSES TO STRESS AND GROWTH WITH CHEMICALS | REMOTE EPIGENETICS INC. (US) | 2025-03-20 | — | — | WO | claimed |
| WO-2024254217-A2 | NOVEL BIOMARKERS FOR ANTITUMOR THERAPIES AND PRDX6 AS A THERAPEUTIC CANCER TARGET | THE REGENTS OF THE UNIVERSITY OF COLORADO A BODY CORPORATE (US) | 2024-12-12 | — | — | WO | claimed |
| WO-2024215661-A1 | BIO-ORTHOGONAL HYDROGELS FOR SUSTAINED RELEASE DRUG DELIVERY | OCULAR THERAPEUTIX, INC. (US) | 2024-10-17 | — | — | WO | claimed |
| WO-2024197137-A2 | POLY(ETHYLENE GLYCOL) BASED DENDRIMER-LIKE HYPERBRANCHED MACROMOLECULES, METHODS OF PREPARATION AND USE THEREOF | OCULAR THERAPEUTIX, INC. (US) | 2024-09-26 | — | — | WO | claimed |
| WO-2024192348-A2 | METHODS OF TREATING HPV IN HIV-INFECTED PATIENTS | OHIO STATE INNOVATION FOUNDATION (US) | 2024-09-19 | — | — | WO | claimed |
| WO-2023147573-A2 | ANTIMICROBIAL HOST DEFENSE PEPTIDE-INDUCING COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF | BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECHANICAL COLLEGES (US) | 2023-08-03 | — | — | WO | claimed |
| US-11701363-B2 | Methods for treating viral disorders | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-07-18 | — | — | US | claimed |
| WO-2022257986-A1 | USE OF CYP450 INHIBITOR IN INHIBITING OR KILLING MITES AND TREATING DRY EYE SYNDROME | 广州岐微生物医药科技有限公司 | 2022-12-15 | — | — | WO | claimed |
| US-20220387546-A1 | Methods For Treating And/Or Preventing Hypersomnias | UNIVERSITE DE LAUSANNE (CH) | 2022-12-08 | — | — | US | claimed |
| EP-4048685-A1 | METHODS FOR TREATING AND/OR PREVENTING HYPERSOMNIAS | Université de Lausanne (CH) | 2022-08-31 | — | — | EP | claimed |
| US-20220249477-A1 | METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS | VIRACTA THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | US | claimed |
| CN-114829386-A | Method for treating and/or preventing hypersomnia | 洛桑大学 | 2022-07-29 | — | — | CN | claimed |
| CN-110755425-B | Application of Largazole in preparation of medicine for treating diseases caused by overexpression of Msi1 gene ectopy | 中国农业大学 | 2022-06-24 | — | — | CN | claimed |
| CN-110117293-B | Polyfluoro-substituted Largazole analogue, preparation method and application thereof | 复旦大学 | 2022-05-10 | — | — | CN | claimed |
| WO-2022058405-A2 | HISTONE DEACETYLASE INHIBITORS AND USES THEREOF | IFOM - ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2022-03-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | HDAC1 493/4885HDAC3 1117/4885HDAC2 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.